Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases, will host a conference call and webcast to discuss its Q2 2025 financial results on Thursday, August 14, 2025, at 8:30 AM ET.
The company will provide updates on its financial performance for the quarter ended June 30, 2025, along with recent business developments. Investors can access the call through U.S. (1-877-407-0789) or International (1-201-689-8562) dial-in numbers using Conference ID 13754425. A replay will be available on the company's website.
Details
News Market Reaction – TRAW
On Aug 8, the day this news came out, TRAW closed 1.35% above the previous close.
Data tracked by StockTitan Argus for the Aug 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.
Conference Call and Webcast Information
- Date: Thursday, August 14, 2025, at 8:30 AM ET
- Participant Dial-in (U.S.): 1-877-407-0789
- Participant Dial-in (International): 1-201-689-8562
- Conference ID: 13754425
- Webcast Access: Click Here
A replay of the webcast will be available on the Investors section of the Traws website at https://www.trawspharma.com/corporate-events-presentations.
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).
Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at https://www.ir.trawspharma.com/partnering.
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.